Prenatal bone marrow transplant for fetuses with Fanconi anemia
Part of Blood & lymphatic, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests giving a bone marrow transplant to a fetus diagnosed with Fanconi anemia while still in the womb. The goal is to help the baby's body make healthy blood cells before birth, potentially reducing complications after birth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The baby must be between 19 and 28 weeks of pregnancy at the time of the transplant.
- The baby must have a confirmed diagnosis of Fanconi anemia from genetic testing during pregnancy.
- Parents must agree to an autopsy if the baby does not survive.
- The mother must be healthy enough to donate bone marrow, with no major heart problems, severe obesity, active preterm labor, or use of blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a reduced-intensity donor stem cell transplant (with briquilimab as part of the conditioning) can safely treat bone marrow failure in people with Fanconi anemia. It may help by lowering how much intensive treatment is needed before the transplant, while still helping the donor cells grow.
This Phase 2 study tests a stem cell transplant approach using adjusted chemotherapy doses for people with Fanconi anemia. It may help replace damaged bone marrow and treat blood problems like severe aplastic anemia, MDS, or leukemia.
This study uses advanced genetic testing to look at the DNA of children with Fanconi anemia and their parents. The goal is to learn more about the genetic causes of the condition, which might help guide future care.
This Phase 2 study tests a special “T-cell depleted” transplant plan for people with inherited bone marrow failure disorders (Fanconi anemia or T-Beta-thalassemia—or “TBD”). It may help restore healthy blood production while lowering the chance of certain transplant complications.
This study looks at how squamous cell carcinoma (a type of cancer) naturally develops over time in people with Fanconi anemia. It may help doctors better recognize warning signs and plan care in the future.
This trial tests whether a gentler (reduced-intensity) conditioning treatment before a stem cell transplant works for non-cancer diseases. It uses specific donor stem cell matches and checks heart, lung, liver, and kidney function to help lower transplant stress while still aiming for benefit.
Hear when a new Fanconi Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.